Multi‑omics

AI-Powered Medical Research & Drug Discovery

by

AI is compressing the time and cost of bringing new therapies to patients by learning the “rules” of biology and chemistry, generating targets and molecules, and optimizing preclinical to clinical decisions—while new regulatory guidance clarifies how AI evidence can support approvals in 2025. Biological foundation models, generative chemistry/protein design, and closed‑loop robotics are moving from … Read more

AI SaaS in Pharma: Accelerating Drug Discovery

by

AI‑powered SaaS accelerates drug discovery by turning scattered biology, chemistry, and lab data into a governed system of action. The durable blueprint: ground hypotheses in permissioned literature, patents, omics, structures, and assay data; use calibrated models for target prioritization, virtual screening, generative design under constraints, and ADMET/PK prediction; simulate project and safety risks; then execute … Read more